BAT Kenya Faces Delay in New Nicotine Pouch Product Launch

BAT by 2FIRSTS.ai
May.07.2024
BAT Kenya Faces Delay in New Nicotine Pouch Product Launch
BAT Kenya's new nicotine pouch production delayed due to lack of regulatory approval, impacting $23.7 million factory operations.

According to the African media outlet BusinessDaily Africa, on May 7, the Kenyan branch of the British American Tobacco Company (BAT) is unable to meet the growing demand for its new nicotine pouch product due to a lack of approval from regulatory authorities. This has resulted in a delay in the operation of their 2.5 billion Kenyan Shilling (approximately 23.7 million US dollars) factory, which was intended to produce new products for the African market.

 

BAT Kenya noted in its annual report that despite strong performance in the local market, the supply chain was disrupted at the end of last year due to the factory still not being operational.

 

BAT Kenya stated in a report that, "We plan to expedite the reduction of tobacco hazards in 2023 and reintroduce our nicotine pouch products in the Kenyan market by 2022. However, by the end of the year, our supply of nicotine pouches in the Kenyan market was disrupted due to regulatory uncertainty. This also affected the commercialization of our modern oral nicotine products manufacturing facility."

 

In 2019, the cigarette manufacturer BAT launched its nicotine pouch brand Lifyt in the Kenyan market for the first time. However, it was banned because it was classified as a pharmaceutical product rather than a tobacco product. The ban was lifted in 2022 after the nicotine pouches were agreed to be classified as tobacco products by the Tobacco Control Committee. BAT reintroduced the product to the market in 2023 under a new brand, Velo. Despite various pressures, the new nicotine pouch manufacturing facility is yet to be implemented.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
BBC survey: over half of secondary teachers in England say vaping is a problem at their school
BBC survey: over half of secondary teachers in England say vaping is a problem at their school
Granville Academy in Swadlincote, Derbyshire, has joined a county pilot overseen by Derbyshire County Council that puts pupils in charge of reducing vaping in school. After reports of pupils stealing vapes, vaping in toilets and using them while walking home, the school found detentions were not effective and shifted to peer-led education sessions, assemblies and health-warning signage.
Feb.05 by 2FIRSTS.ai
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s National School Health Survey (PeNSE) 2024 found that e-cigarette experimentation among students aged 13 to 17 rose from 16.8% in 2019 to 29.6% in 2024, while use in the previous 30 days increased from 8.6% to 26.3%. Over the same period, conventional cigarette experimentation fell from 22.6% to 18.5%, and hookah use declined from 26.9% to 16.4%.
Mar.26 by 2FIRSTS.ai
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
The Kansas Senate approved Senate Bill 355 on Wednesday, aiming to crack down on unlicensed vaping products and eliminate advertisements geared toward children. The bill, backed by major tobacco companies, would impose the same licensing and advertising requirements on e-cigarettes as other nicotine products and require every e-cigarette manufacturer doing business in Kansas to obtain a license, with a $2,500 application fee.
Feb.13 by 2FIRSTS.ai
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
The U.S. International Trade Commission (ITC) has terminated Investigation 337-TA-1410 after invalidating key vape patent claims asserted by R.J. Reynolds Vapor Company, removing the immediate risk of import bans for dozens of companies. However, a new case—337-TA-1486—has already opened a more consequential legal front, shifting the focus from patent disputes to regulatory compliance across the vape supply chain, including PACT Act reporting, tax compliance, and FDA marketing authorization.
BAT
Mar.11